Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

INTRODUCTION: NSCLC with MET exon 14 skipping mutation (METex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatment patterns, outcomes, and emerging issues of tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Sally C.M., Perdrizet, Kirstin, Fung, Andrea S., Mata, Danilo Giffoni M.M., Weiss, Jessica, Holzapfel, Nick, Liu, Geoffrey, Bradbury, Penelope A., Shepherd, Frances A., Sacher, Adrian G., Feilotter, Harriet, Sheffield, Brandon, Hwang, David, Tsao, Ming Sound, Cheng, Susanna, Cheema, Parneet, Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514105/
https://www.ncbi.nlm.nih.gov/pubmed/37744308
http://dx.doi.org/10.1016/j.jtocrr.2023.100562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514105/
https://www.ncbi.nlm.nih.gov/pubmed/37744308
http://dx.doi.org/10.1016/j.jtocrr.2023.100562

Ejemplares similares